Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companies (‘Vants’) focused on various therapeutic areas and built around the pursuit of innovation in drug development and technology.
Our model is different. Five new medicines have been approved off the Roivant platform; we’ve built five biotechs that have become public; we’ve created well over $1b in value in Roivant Health in just six years. Our successes have ranged from computational drug discovery to tokenized healthcare data exchange, and from novel topicals for dermatological conditions to ultrarare tissue therapies.
Roivant Health is Roivant’s platform for the creation of new technology Vants, focused on delivering improvements to human health outside of our traditional biotech platform. In six years since inception, we’ve created eight enduring companies and over $1B in enterprise value, including the leading deidentified healthcare data exchange platform (Datavant) and a top-tier computational drug discovery company (VantAI) which has partnered with Johnson & Johnson, Bristol-Myers Squibb, and Boehringer Ingelheim. Our goal is to improve human health by rapidly discovering, developing and delivering innovative medicines and technologies to all patients. Our success is predicated on attracting and retaining top talent, generating new ideas and promoting an open and collaborative culture.
